You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Expert Opinion: Use of Adjuvant and Neoadjuvant Approaches in Patients With Stage III Melanoma

  1. Which of the following outcomes is representative of the updated analysis of KEYNOTE-716, which evaluated patients with newly diagnosed, completely resected cutaneous stage IIB or IIC melanoma randomized to pembrolizumab or placebo?
    Adjuvant pembrolizumab significantly improved distant metastasis-free survival (DMFS)
    Adjuvant pembrolizumab showed no DMFS benefit
    Adjuvant pembrolizumab significantly improved overall survival (OS)
  2. Which of the following agents or combinations are not approved as adjuvant therapy for stage III disease?
    Dabrafenib plus trametinib
    Nivolumab plus ipilimumab